CR20130312A - Respuesta inmune potenciada en la especie bovina - Google Patents
Respuesta inmune potenciada en la especie bovinaInfo
- Publication number
- CR20130312A CR20130312A CR20130312A CR20130312A CR20130312A CR 20130312 A CR20130312 A CR 20130312A CR 20130312 A CR20130312 A CR 20130312A CR 20130312 A CR20130312 A CR 20130312A CR 20130312 A CR20130312 A CR 20130312A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bovine species
- immune response
- potentiated
- response potentiated
- bovine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un procedimiento de activación inmune que es efectivo para provocar una respuesta inmune no específica para antígenos en un miembro de la especie bovina. El procedimiento es particularmente efectivo para proteger un miembro de la especie bovina de enfermedades infecciosas y tratar animales afectados de una enfermedad infecciosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426255P | 2010-12-22 | 2010-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130312A true CR20130312A (es) | 2013-10-17 |
Family
ID=45444595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130312A CR20130312A (es) | 2010-12-22 | 2013-06-21 | Respuesta inmune potenciada en la especie bovina |
Country Status (34)
Country | Link |
---|---|
US (3) | US20130295167A1 (es) |
EP (1) | EP2654785B1 (es) |
JP (2) | JP6058550B2 (es) |
KR (1) | KR101940826B1 (es) |
CN (2) | CN108379576A (es) |
AR (1) | AR084510A1 (es) |
AU (1) | AU2011347464B2 (es) |
BR (1) | BR112013016231B1 (es) |
CA (1) | CA2822359C (es) |
CL (1) | CL2013001833A1 (es) |
CO (1) | CO6761354A2 (es) |
CR (1) | CR20130312A (es) |
DK (1) | DK2654785T3 (es) |
DO (1) | DOP2013000149A (es) |
EC (1) | ECSP13012709A (es) |
ES (1) | ES2722204T3 (es) |
GT (1) | GT201300168A (es) |
HK (1) | HK1259341A1 (es) |
HR (1) | HRP20190779T1 (es) |
HU (1) | HUE043473T4 (es) |
IL (1) | IL226733B (es) |
LT (1) | LT2654785T (es) |
MX (1) | MX345854B (es) |
MY (1) | MY167159A (es) |
NZ (1) | NZ612285A (es) |
PL (1) | PL2654785T3 (es) |
PT (1) | PT2654785T (es) |
RU (1) | RU2606855C2 (es) |
SI (1) | SI2654785T1 (es) |
TR (1) | TR201906323T4 (es) |
TW (1) | TWI587877B (es) |
UA (1) | UA118537C2 (es) |
UY (1) | UY33821A (es) |
WO (1) | WO2012084951A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2654785B1 (en) * | 2010-12-22 | 2019-03-20 | Bayer Intellectual Property GmbH | Enhanced immune response in bovine species |
JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
MX2016010993A (es) | 2014-02-28 | 2017-05-01 | Bayer Animal Health Gmbh | Plasmidos inmunoestimuladores. |
CN104825393B (zh) * | 2015-01-16 | 2017-11-10 | 艾美科健(中国)生物医药有限公司 | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 |
US20190233825A1 (en) * | 2015-06-26 | 2019-08-01 | Bayer Animal Health Gmbh | Methods of modulating cytosolic dna surveillance molecules |
CA2993883A1 (en) | 2015-07-31 | 2017-02-09 | Bayer Animal Health Gmbh | Enhanced immune response in porcine species |
JP2018521108A (ja) * | 2015-07-31 | 2018-08-02 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh | 水生種における免疫応答の増強 |
AU2017301528A1 (en) * | 2016-07-26 | 2019-02-14 | Bayer Animal Health Gmbh | Increased fertility in bovine species |
KR102069680B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
SG11202004773SA (en) * | 2017-12-15 | 2020-06-29 | Bayer Animal Health Gmbh | Immunostimulatory compositions |
CN108812546A (zh) * | 2018-09-07 | 2018-11-16 | 四川省草原科学研究院 | 适于青藏高原地区牦牛运输减少应激的药物及使用方法 |
CN109646435B (zh) * | 2019-01-11 | 2021-08-03 | 山东省农业科学院奶牛研究中心 | 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用 |
US11689594B2 (en) | 2019-03-28 | 2023-06-27 | Nec Corporation | Information processing apparatus, server allocation apparatus, method, and computer readable medium |
CN114480663A (zh) * | 2021-11-15 | 2022-05-13 | 贵州省畜牧兽医研究所 | 用于检测猪源差异脲原体的引物对、试剂盒及检测方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5427791A (en) | 1992-08-05 | 1995-06-27 | Regents Of The University Of Minnesota | Embryonal vaccine against Newcastle disease |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5830878A (en) * | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US6048535A (en) | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6586409B1 (en) | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
RU2158587C1 (ru) * | 1999-05-11 | 2000-11-10 | Ставропольское научно-производственное объединение "Пульс" | Антибактериальное средство для лечения заболеваний сельскохозяйственных животных и птиц, способ профилактики и лечения цыплят при заболеваниях бактериальной этиологии, способ лечения респираторной болезни телят бактериальной этиологии, способ профилактики туберкулеза у крупного рогатого скота |
US20040002472A1 (en) * | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
MXPA03009632A (es) | 2001-04-24 | 2004-06-30 | Innogenetics Nv | Proteinas de la envoltura de vhc glucosiladas en la estructura central. |
JP2004537543A (ja) * | 2001-07-02 | 2004-12-16 | ファイザー・プロダクツ・インク | マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法 |
BRPI0408779A (pt) * | 2003-03-26 | 2006-04-04 | Wyeth Corp | uso de composições, composição imunogênica e kit |
AR044437A1 (es) * | 2003-05-29 | 2005-09-14 | Schering Plough Ltd | Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino |
AU2004280143A1 (en) * | 2003-10-11 | 2005-04-21 | Tekmira Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
UY29915A1 (es) | 2005-11-15 | 2007-06-29 | Boehringer Ingelheim Vetmed | Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina |
JP2008094763A (ja) * | 2006-10-12 | 2008-04-24 | Takeshi Ogura | 海洋ミネラル成分からなるインターフェロンγ産生増強剤 |
EP2249843A4 (en) * | 2008-02-24 | 2013-05-08 | Us Gov Health & Human Serv | USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGENIC INFECTIONS |
CA2719614C (en) * | 2008-03-25 | 2018-05-01 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
US8815255B2 (en) * | 2008-10-31 | 2014-08-26 | Boehringer Ingelheim Vetmedica, Inc. | Use of Mycoplasma bovis antigen |
WO2010130374A1 (en) | 2009-05-14 | 2010-11-18 | Bayer Animal Health Gmbh | Enhanced immune response in avian species |
EP2654785B1 (en) | 2010-12-22 | 2019-03-20 | Bayer Intellectual Property GmbH | Enhanced immune response in bovine species |
-
2011
- 2011-12-20 EP EP11804675.4A patent/EP2654785B1/en active Active
- 2011-12-20 US US13/995,960 patent/US20130295167A1/en not_active Abandoned
- 2011-12-20 NZ NZ612285A patent/NZ612285A/en unknown
- 2011-12-20 HU HUE11804675A patent/HUE043473T4/hu unknown
- 2011-12-20 SI SI201131729T patent/SI2654785T1/sl unknown
- 2011-12-20 MY MYPI2013701066A patent/MY167159A/en unknown
- 2011-12-20 BR BR112013016231-7A patent/BR112013016231B1/pt active IP Right Grant
- 2011-12-20 CA CA2822359A patent/CA2822359C/en active Active
- 2011-12-20 RU RU2013133730A patent/RU2606855C2/ru active
- 2011-12-20 CN CN201810200992.0A patent/CN108379576A/zh active Pending
- 2011-12-20 WO PCT/EP2011/073414 patent/WO2012084951A1/en active Application Filing
- 2011-12-20 PL PL11804675T patent/PL2654785T3/pl unknown
- 2011-12-20 DK DK11804675.4T patent/DK2654785T3/da active
- 2011-12-20 KR KR1020137018801A patent/KR101940826B1/ko active IP Right Grant
- 2011-12-20 JP JP2013545307A patent/JP6058550B2/ja active Active
- 2011-12-20 ES ES11804675T patent/ES2722204T3/es active Active
- 2011-12-20 UY UY0001033821A patent/UY33821A/es not_active Application Discontinuation
- 2011-12-20 MX MX2013007064A patent/MX345854B/es active IP Right Grant
- 2011-12-20 TR TR2019/06323T patent/TR201906323T4/tr unknown
- 2011-12-20 PT PT11804675T patent/PT2654785T/pt unknown
- 2011-12-20 AU AU2011347464A patent/AU2011347464B2/en active Active
- 2011-12-20 UA UAA201308922A patent/UA118537C2/uk unknown
- 2011-12-20 LT LTEP11804675.4T patent/LT2654785T/lt unknown
- 2011-12-20 CN CN201180066905.3A patent/CN103501810A/zh active Pending
- 2011-12-21 AR ARP110104848A patent/AR084510A1/es unknown
- 2011-12-21 TW TW100147617A patent/TWI587877B/zh active
-
2013
- 2013-06-04 IL IL226733A patent/IL226733B/en active IP Right Grant
- 2013-06-20 CL CL2013001833A patent/CL2013001833A1/es unknown
- 2013-06-21 GT GT201300168A patent/GT201300168A/es unknown
- 2013-06-21 CO CO13148228A patent/CO6761354A2/es not_active Application Discontinuation
- 2013-06-21 CR CR20130312A patent/CR20130312A/es unknown
- 2013-06-21 EC ECSP13012709 patent/ECSP13012709A/es unknown
- 2013-06-21 DO DO2013000149A patent/DOP2013000149A/es unknown
- 2013-06-21 US US13/923,496 patent/US20140010865A1/en not_active Abandoned
-
2016
- 2016-09-12 JP JP2016177599A patent/JP2017036290A/ja active Pending
-
2018
- 2018-08-08 US US16/058,888 patent/US10751361B2/en active Active
-
2019
- 2019-01-31 HK HK19101707.1A patent/HK1259341A1/zh unknown
- 2019-04-25 HR HRP20190779TT patent/HRP20190779T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012709A (es) | Respuesta inmune potenciada en la especie bovina | |
CR20110595A (es) | Respuesta inmunitaria reforzada en especies aviares | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
UY34995A (es) | Formulaciones de anticuerpo y proteína | |
GT201300306A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
CR20120404A (es) | Proteinas de enlace cd127 | |
EA201790109A1 (ru) | Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки | |
ECSP14020644A (es) | Anticuerpos dirigidos contra metaloproteinasas de matriz 9 | |
BR112014020019A8 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitas a partir destes | |
BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
ECSP13012673A (es) | Métodos y composiciones para inmunoterapia para enfermedad neural | |
CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
CO2018002207A2 (es) | Composiciones contra alergia a los gatos | |
IN2014CN04071A (es) | ||
CO2019001112A2 (es) | Anticuerpos con inmunogenicidad baja y usos de estos referencia cruzada a solicitudes relacionadas | |
CR20140121A (es) | Formulaciones para los campos de arrozales | |
MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
BR112017007860A2 (pt) | método para tratar uma doença de gordura no fígado | |
MX2017000869A (es) | Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas. | |
NI201300058A (es) | Respuesta inmune potenciada en la especie bovina | |
BR112012022680A2 (pt) | métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina | |
BR112015028986A2 (pt) | métodos para produzir partículas compreendendo proteínas terapêuticas | |
NZ629420A (en) | Sheep nematode vaccine | |
AR083637A1 (es) | Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas a enfermedades neurodegenerativas |